J Neuroimmunol. 2004 Jun;151(1-2):180-8
DeRijk RH, Eskandari F, Sternberg EM.
Section in Neuroendocrine Immunology and Behavior, National Institute of Mental Health, 36 Convent Drive (MSC 4020), Bethesda, MD 20892-4020, USA.
We assessed corticosteroid sensitivity in multiple sclerosis (MS) patients compared to control subjects, using an in vitro assay of dexamethasone (Dex) inhibition of lipopolysaccharide (LPS) stimulated-blood interleukin-6 production.
Significantly higher concentrations of dexamethasone were needed to obtain 50%-inhibition (ID(50)) of in vitro LPS stimulated interleukin (IL)-6 production (28.4x10(-7) M) in relapsing-remitting MS (RRMS) patients compared to chronic progressive MS (CPMS) patients (6.2x10(-7) M) or compared to controls (3.0x10(-7) M).
We also found a trend towards worsening of clinical status over time with increasing corticosteroid resistance.
These data suggest that corticosteroid sensitivity may be a factor in the pathogenesis and could be used for prognosis of MS.